Adjupharm, the German subsidiary of IM Cannabis Corp, will provide EU Good Manufacturing Practice quality medical cannabis to Farmako for a three-year term
AgraFlora Organics International Inc () said its subsidiary Farmako GmbH has entered into a binding distribution agreement with Adjupharm GmbH to supply medical cannabis in Germany.
Adjupharm, the German subsidiary of (), will provide EU Good Manufacturing Practice (GMP) quality medical cannabis to Farmako for a three-year term, according to a statement.
Farmako will distribute the products in Germany to patients under the brand to its established network of German pharmacies. The first products are expected to launch in October 2020.
READ: AgraFlora says Farmako subsidiary secures added supply of EU-GMP certified medical cannabis from ZenPharm
The products provided by Adjupharm and distributed by Farmako include initially high potency THC flower. The portfolio is expected to be enhanced throughout the first quarter of 2021 by balanced THC and CBD flower as well as CBD dominant flower.
“We believe that Adjupharm’s IMC branded cannabis is a great fit for our product portfolio,” said Farmako CEO Katrin Eckmans.
"Our goal is to provide a comprehensive and sustainable portfolio of high-quality medical cannabis products, including both flower and ‘2.0’ ingestible products to patients in Germany. We believe Farmako’s established pharmacy network combined with IMC’s quality and manufacturing excellence will be a disruptive force in Germany’s rapidly evolving medical cannabis market.”
In addition to the IMC branded cannabis produced and procured by the distribution agreement, AgraFlora said Farmako intends to launch additional in-house and third party branded medical cannabis products this year.
Contact the author: patrick@proactiveinvestors.com
Follow him on Twitter @PatrickMGraham
